Clinical relevance of PD-L1 expression and CD8 T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · see citing works

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · see citing works

The immune contexture in cancer prognosis and treatment

Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · see citing works

Classifying Cancers Based on T-cell Infiltration and PD-L1

Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,412 · see citing works

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,256 · see citing works

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959 · see citing works

Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936 · see citing works

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

D’Incecco, A., Andreozzi, M., Ludovini, V., Rossi, E., Capodanno, A., Landi, L. M., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.555 · Cited by 594 · see citing works

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30144-x · Cited by 568 · see citing works

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440 · see citing works

Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer

Dønnem, T., Hald, S. M., Paulsen, E., Richardsen, E. H., Al‐Saad, S., Kilvaer, T. K., Brustugun, O. T., Helland, Å., Lund‐Iversen, M., Poehl, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1905 · Cited by 308 · see citing works

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx183 · Cited by 295 · see citing works

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes

He, Y., Yu, H., Rozeboom, L. M., Rivard, C. J., Ellison, K. E., Dziadziuszko, R., Suda, K., Ren, S., Wu, C., Hou, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.019 · Cited by 269 · see citing works

Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Mazzaschi, G., Madeddu, D., Falco, A., Bocchialini, G., Goldoni, M., Sogni, F., Armani, G., Lagrasta, C. A., Lorusso, B., Mangiaracina, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2156 · Cited by 252 · see citing works

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

Tu, H.-Y., Ke, E.-E., Yang, J.-J., Sun, Y.-L., Yan, H.-H., Zheng, M.-Y., Bai, X.-Y., Wang, Z., Su, J., Chen, Z.-H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.005 · Cited by 182 · see citing works

Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy

Zhang, Y. X., & Chen, L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2450 · Cited by 168 · see citing works

Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma

Lee, B. S., Park, D. I., Lee, D. H., Lee, J. E., Yeo, M., Park, Y., Lim, D., Choi, W., Lee, D. H., Yoo, G., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.007 · Cited by 166 · see citing works

Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma

Yang, C., Lin, M., Chang, Y., Wu, C., & Yang, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.033 · Cited by 122 · see citing works

Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients

Remark, R., Mansuet‐Lupo, A., Alifano, M., Biton, J., Ouakrim, H., Stefani, A. D., Cremer, I., Goc, J., Régnard, J., Dieu‐Nosjean, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1255394 · Cited by 85 · see citing works

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer

Bylicki, O., Paleiron, N., Margery, J., Guisier, F., Vergnenégre, A., Robinet, G., Auliac, J. B., Gervais, R., & CHOUAID, C. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0510-9 · Cited by 79 · see citing works

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Liu, S. M., & Wu, Y.-L. L. C. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0506-z · Cited by 63 · see citing works

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Gettinger, S. N., & Politi, K. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1401 · Cited by 40 · see citing works

Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer

Hata, A., Katakami, N., Nanjo, S., Okuda, C., Kaji, R., Masago, K., Fujita, S., Yoshida, H., Zama, K., Imai, Y., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.022 · Cited by 38 · see citing works

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

Roussel, H., de Guillebon, E., Biard, L., Mandavit, M., Gibault, L., Fabre, E., Antoine, M., Hofman, P., Beau-Faller, M., Blons, H., et al. (2017) · Oncoimmunology · doi:10.1080/2162402x.2017.1286437 · Cited by 25 · see citing works

Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer

Kim, T. J., Hong, S. A., Kim, O., Kim, S. J., Yang, J., Joung, E. K., Kang, J., & Hong, S. H. (2017) · Oncotarget · doi:10.18632/oncotarget.22582 · Cited by 22 · see citing works

A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study

Hayashi, H., Chiba, Y., Sakai, K., Fujita, T., Yoshioka, H., Sakai, D., Kitagawa, C., Naito, T., Takeda, K., Okamoto, I., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.012 · Cited by 17 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 292 · see citing works

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies

Johnson, M. L., Garassino, M. C., Mok, T. S. K., & Mitsudomi, T. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.011 · Cited by 156 · see citing works

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

Dantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 142 · see citing works

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136 · see citing works

Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?

Hofman, P. M., Badoual, C., Henderson, F., Berland, L., Hamila, M., Long-Mira, É., Lassalle, S., Roussel, H., Hofman, V., Tartour, É., et al. (2019) · Cancers · doi:10.3390/cancers11030283 · Cited by 114 · see citing works

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110 · see citing works

Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer

Yin, X., Liao, H., Hong, Y., Lin, N., Li, S., Xiang, Y., & Ma, X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.002 · Cited by 110 · see citing works

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

Shi, Y., Lei, Y., Liu, L., Zhang, S., Wang, W., Zhao, J., Zhao, S., Dong, X., Yao, M., Wang, K., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3649 · Cited by 106 · see citing works

Emerging evidence and treatment paradigm of non-small cell lung cancer

Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 105 · see citing works

Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC

Tian, Y., Zhai, X., Yan, W., Zhu, H., & Yu, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3590 · Cited by 58 · see citing works

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

Budczies, J., Kirchner, M., Kluck, K., Kazdal, D. N., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J. F., Winter, H., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02981-w · Cited by 49 · see citing works

Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer

Kim, S., Go, S., Song, D. H., Park, S., Kim, H. R., Jang, I. S., Kim, J. D., Lee, J. S., & Lee, G. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0398-5 · Cited by 45 · see citing works

Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions

Parvaresh, H., Roozitalab, G., Golandam, F., Behzadi, P., & Kaboli, P. J. (2024) · Biomedicines · doi:10.3390/biomedicines12020297 · Cited by 47 · see citing works

Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor‐tyrosine kinase inhibitors in patients with EGFR ‐mutant non‐small cell lung cancer

Matsumoto, Y., Sawa, K., Fukui, M., Oyanagi, J., Izumi, M., Ogawa, K., Suzumura, T., Watanabe, T., Kaneda, H., Mitsuoka, S., et al. (2019) · Cancer Science · doi:10.1111/cas.14156 · Cited by 41 · see citing works

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis

Guaitoli, G., Tiseo, M., Maïo, M. D., Friboulet, L., & Facchinetti, F. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-941 · Cited by 37 · see citing works

B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma

Chen, Y., Hu, R., Li, X., Zhongyuan, S., Tian, H., Feng, J., & Yu, S. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153134 · Cited by 32 · see citing works

Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review

Liu, L., Wang, C., Li, S., Bai, H., & Wang, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-572 · Cited by 32 · see citing works

Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches

Sankar, K. N., Nagrath, S., & Ramnath, N. (2021) · Cancers · doi:10.3390/cancers13061476 · Cited by 30 · see citing works

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

Chen, Y., Yang, Z., Wang, Y., Hu, M., Zhang, B., Zhang, Y., Qian, F., Zhang, W., & Han, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671228 · Cited by 28 · see citing works

Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer

Shirasawa, M., Yoshida, T., Imabayashi, T., Okuma, K., Matsumoto, Y., Masuda, K., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.013 · Cited by 28 · see citing works

The Relationship between Lymphocyte Subsets and the Prognosis and Genomic Features of Lung Cancer: A Retrospective Study

Dai, S., Ren, P., Ren, J. L., Yang, L., & Li, W. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.56928 · Cited by 23 · see citing works

Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation

Zhang, B., Zeng, J., Zhang, H., Zhu, S., Wang, H., He, J., Yang, L., Zhou, N., Zu, L., Xu, X. N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974581 · Cited by 23 · see citing works

Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives

Kato, T., Casarini, I., Cobo, M., Finn, C. F., Hegi‐Johnson, F., Lü, S., Özgüroğlu, M., & Ramalingam, S. S. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107414 · Cited by 21 · see citing works

Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacy

Vion, R., Dugage, M. R., Flippot, R., Ouali, K., Rouanne, M., Clatot, F., Sellars, M., Champiat, S., Chaput, N., Massard, C., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115572 · Cited by 20 · see citing works

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity

Kleczko, E. K., Hinz, T. K., Nguyen, T. T., Gurule, N. J., Navarro, A., Le, A. T., Johnson, A. M., Kwak, J., Polhac, D. I., Clambey, E. T., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00355-2 · Cited by 20 · see citing works

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Wang, M., Zhu, L., Yang, X., Li, J., Liu, Y., & Ying, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1132158 · Cited by 20 · see citing works

TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis

Jiang, B., Hu, L., Dong, D., Guo, Z., Wei, W., Wang, C., Shao, W., Ma, T., Chen, Y., Li, Q., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04924-7 · Cited by 20 · see citing works

Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma

Tashiro, T., Imamura, K., Tomita, Y., Tamanoi, D., Takaki, A., Sugahara, K., Sato, R., Saruwatari, K., Sakata, S., Inaba, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249705 · Cited by 19 · see citing works

Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma

Yin, K., Feng, H., Li, L., Chen, Y., Xie, Z., Lv, Z., Guo, W., Lu, D., Yang, X., Yan, W., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13271 · Cited by 19 · see citing works

The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC

Lan, B., Wang, Y., Wu, J., Wang, K., & Wang, P. (2021) · Medicine · doi:10.1097/md.0000000000027038 · Cited by 17 · see citing works

Battlegrounds of treatment resistance: decoding the tumor microenvironment

Bayat, M., & Nahand, J. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04055-5 · Cited by 16 · see citing works

Boosting immune responses in lung tumor immune microenvironment: A comprehensive review of strategies and adjuvants

Gao, F., You, X., Yang, L., Zou, X., & Sui, B. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2333275 · Cited by 14 · see citing works

Biomarker for personalized immunotherapy

Liu, S. M., & Wu, Y.-L. L. C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.02 · Cited by 14 · see citing works

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer

Lei, S., Xu, H., Li, H., Yang, Y., Xu, F., Li, J., Wang, Z., Xing, P., Hao, X., & Wang, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15021 · Cited by 13 · see citing works

Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas

Goldschmid, H., Kluck, K., Ball, M., Kirchner, M., Allgäuer, M., Winter, H., Herth, F. J. F., Heußel, C. P., Pullamsetti, S. S., Savai, R., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107212 · Cited by 12 · see citing works

Integrative transcriptome analysis reveals the molecular events underlying impaired T-cell responses in EGFR-mutant lung cancer

Zhao, Y., Tang, G., Li, J., Bian, X., Zhou, X., & Feng, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-69020-3 · Cited by 12 · see citing works

Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors

Malhotra, J. D., De, S., Nguyen, K., Lee, P. P., & Villaflor, V. M. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03825-z · Cited by 12 · see citing works

Elevated Pretreatment Fibrinogen-to-Lymphocyte Percentage Ratio Predict Tumor Staging and Poor Survival in Non-Small Cell Lung Cancer Patients with Chemotherapy or Surgery Combined with Chemotherapy

Liu, M., Yang, J., Wan, L., & Zhao, R. (2021) · Cancer Management and Research · doi:10.2147/cmar.s308659 · Cited by 12 · see citing works

Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib

Zhou, Y., Song, L., Xu, Q., Zeng, L., Jiang, W., Yang, N., & Zhang, Y. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.04.002 · Cited by 11 · see citing works

Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation

Cheng, Y., Yang, B., Ouyang, W., Chen, J., Zhang, W., Chen, G., Zhang, J., Yu, J., & Xie, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.920047 · Cited by 11 · see citing works

EGFR-Driven Mutation in Non-Small-Cell Lung Cancer (NSCLC) Influences the Features and Outcome of Brain Metastases

Pesce, A., Armocida, D., Palmieri, M., Cofano, F., Mantovani, S., Perna, G., Palmieri, G., Cassoni, P., Salvati, M., Antonelli, M., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103372 · Cited by 10 · see citing works

Cancer patient stratification based on the tumor microenvironment

Ying, L., Yan, F., & Xu, D. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.77 · Cited by 10 · see citing works

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma

Wang, H., Chen, S., Meng, D., Wu, C., Zhu, J., Jiang, M., Ning, J., Wu, S., Wu, L., Li, J., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s294993 · Cited by 10 · see citing works

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations

Yang, Y., Zhang, X., Gao, Y., Dong, Y., Wang, D., Huang, Y., Qu, T., Fan, B., Li, Q., Zhang, C., et al. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504022x16462176651719 · Cited by 7 · see citing works

New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer

Long, M., Peng, S., Wen, Q., Yin, Z., Zhang, X., Tan, H., Xu, Y., & Wu, Y. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.122 · Cited by 6 · see citing works

PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors

Lasvergnas, J., Fallet, V., Duchemann, B., Jouveshomme, S., Cadranel, J. L., & CHOUAID, C. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.101018 · Cited by 6 · see citing works

Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance

Li, Y., Jiang, H., Qian, F., Chen, Y., Zhou, W., Zhang, Y., Lü, J., Lou, Y., Han, B., & Zhang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161718 · Cited by 6 · see citing works

Tumor Immune Microenvironment of EGFR -mutant Non-Small-Cell Lung Cancer and its Impact on Therapeutic Efficacy

Matsumoto, Y., & Koh, Y. (2020) · Immunotherapy · doi:10.2217/imt-2019-0213 · Cited by 6 · see citing works

Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements

Zou, Y., Zhao, J., Huang, F., Xiang, X., & Xia, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195935 · Cited by 5 · see citing works

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

Leone, G., Passiglia, F., Bironzo, P., Bertaglia, V., & Novello, S. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-710 · Cited by 4 · see citing works

Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis

Hu, R., Zhao, Z., Shi, Y., Shi, M., Xia, G., Yu, S., & Feng, J. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3520 · Cited by 5 · see citing works

Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score

Liu, S. M., Sun, H., Zhou, J., Zhang, J., Yin, K., Chen, Z., Su, J., Zhang, X., Yang, J., Zhou, Q. H., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101254 · Cited by 5 · see citing works

Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancerPreprint

Kleczko, E. K., Hinz, T. K., Nguyen, T. T., Gurule, N. J., Navarro, A., Le, A. T., Johnson, A. M., Kwak, J., Polhac, D. I., Clambey, E. T., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.14.488385 · Cited by 4 · see citing works

Immunotherapy in Advanced Non-Small-Cell Lung Cancer with EGFR Mutations

Liu, F., Yuan, X., Jiang, J., & Chu, Q. (2020) · Immunotherapy · doi:10.2217/imt-2020-0148 · Cited by 3 · see citing works

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy

Cao, P., Zhao, Q., Li, Y., Shi, R., Zhu, G., Zhang, Z., Zhang, H., Liu, M., Wei, S., Liu, H., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1140894 · Cited by 3 · see citing works

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Shang, X., Zhang, W., Han, W., Xia, H., Liu, G., Wang, X., & Liu, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02707-x · Cited by 3 · see citing works

[A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations].

Du, W., Wo, Y., Lu, T., Wang, Y., & Jiao, W. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.09.07 · Cited by 3 · see citing works

Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients

Wang, S., Qu, X., Li, Z., Che, X., Cao, L., Yang, X., Hu, X., Xu, L., Hou, K., Fan, Y., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-968 · Cited by 2 · see citing works

Immunotherapy and PD-L1 Tumor Expression in Moroccan Non-Small Cell Lung Cancer Patients with Various Metastasis

Aazzane, O., Fathi, S., Charkaoui, M., Acharki, A., Sahraoui, S., Benchakroun, N., Fellah, H., & Karkouri, M. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.8.2841 · Cited by 2 · see citing works

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].

Deng, R., Zeng, Y., Pan, Y., Hu, C., & Wu, F. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.06 · Cited by 2 · see citing works

Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report

Wang, H., Wu, Z., Shi, G., Zhou, J., & Xiao, Z. (2023) · Oncology Letters · doi:10.3892/ol.2023.14113 · Cited by 2 · see citing works

Exploring the Role of Immunotherapy-Based Treatments for Advanced Non–Small-Cell Lung Cancer With Novel Driver Alterations

Brambilla, M., Beninato, T., Piemontese, A., Mazzeo, L., Pircher, C. C., Manglaviti, S., Ambrosini, P., Signorelli, D., Lorenzini, D., Prelaj, A., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.08.004 · Cited by 2 · see citing works

Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations

Liu, S. M., & Wu, Y.-L. L. C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.020 · Cited by 2 · see citing works

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression

Abdayem, P., & Planchard, D. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-628 · Cited by 1 · see citing works

A Novel DNA Repair‐Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR ‐Mutant Non‐Small Cell Lung Cancer

Wang, F., Wei, X., Yang, M., Lu, C., Yang, X., Deng, J., Chen, Z., & Zhou, Q. H. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70025 · Cited by 1 · see citing works

Co-expression pattern of CD8, CXCR5 and CXCL13 in tumor microenvironment predicts favorable efficacy of immunotherapy in lung adenocarcinoma

Zhong, S.-M., Guo, S.-Y., Yang, Y.-J., Chen, C., Zhang, D.-D., Wu, Y.-L., Yq, L., Jin, Z.-Y., & Liu, S.-Y. M. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178691 · Cited by 1 · see citing works

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China

Zhang, C., Jiang, B., Yan, L.-X., Peng, L., Li, J.-H., Chen, Z.-Y., Sun, Y.-X., su, J., Liao, R.-Q., Dong, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103994 · Cited by 1 · see citing works

Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies

Loh, J., Ang, Y. L. E., Jain, A., Yeong, J. P.-S., & Sundar, R. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00208 · Cited by 1 · see citing works

Towards New Promising Discoveries for Lung Cancer Patients: A Selection of Papers from the First Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA)

Calin, G., Hofman, P. M., & Mani, S. A. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-452-5

Tumor immune microenvironment in non-small cell lung cancer with EGFR mutation before and after EGFR-TKIs treatmentPreprint

wang, C., liu, L., li, S., Bai, H., & Wang, J. (2021) · doi:10.22541/au.161393354.40757172/v1

Delivery strategies to overcome tumor immunotherapy resistance

Su, L., Chen, G., Liu, Z., Min, Y., & Wang, A. Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00019-1

Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)

Ozawa, Y., Koh, Y., Hase, T., Chibana, K., Kaira, K., Okishio, K., Ichihara, E., Murakami, S., Shimokawa, M., & Yamamoto, N. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225046

A Prospective Exploratory Study of Functional Immunity Assessed by Pretreatment Interferon Gamma Release Assay in Relation to Different Systemic Therapies in Patients With Advanced-Stage NSCLC

Huang, H.-C., Chang, H.-J., Chiang, C., Huang, H., Luo, Y., Chen, Y.-M., Shiao, T., & Chiu, C. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100845

A Decade of Treating ALK-Rearranged Non-Small Cell Lung Cancer in a Lower Middle-Income Country: Changing Patterns and Improving Survival

Batra, U., Sharma, M., Ahmad, I., Rajappa, S. J., Nathany, S., Cantini, L., Sachdeva, R., Batra, V., Choudhury, R., Agarwal, B., et al. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00390-y

Additional file 1 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24669938

Additional file 6 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26647272

Additional file 5 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26647269

Additional file 4 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26647266

Additional file 3 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26647263

Additional file 2 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Shang, X., Zhang, W., Han, W., Xia, H., Liu, N., Wang, X., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.24670377

Contribution à l'identification de marqueurs de la réponse des carcinomes bronchiques non à petites cellules aux immunothérapies

Guisier, F. (2019) · doi:10.70675/9de2ee5az6556z48b7z97b1zc402c970fc69

The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib

Mizutani, M., Matsumoto, Y., Ohe, C., Sugimoto, A. K., Nagamine, H., Tani, Y., Oka, T., Kaneda, H., Yamada, K., Watanabe, T., et al. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.09.003

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma

Yang, Y., Zhang, J., Xie, Z., & Zhang, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1766882

Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management

Wang, Y.-Z., Wang, Y.-G., Pan, Y., Gang, X., Yan, J., Wang, X., Tang, H.-L., Li, H.-M., & Zhao, M. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218703

Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).

Gainor, J. F., Sequist, L. V. D., Shaw, A. T., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Fulton, L. E., Schultz, K. R., Hata, A. N., Engelman, J. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8012 · Cited by 26 · see citing works

1253P Clinical relevance of immune factors beyond CD8+T cells and mutation status of EGFR and ALK in patients with non-small cell lung cancer

Wang, K., Zhang, H., Wang, X., Liu, Y., Duan, J., Lei, Y., She, X., Shen, X., & Huang, D. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.126

P1.07-042 PD-L1 and CD8 Expression in EGFR-Mutant or ALK-Rearranged Patients with Lung Cancer

Liu, S., Dong, Z., Wu, S.-P., Xie, Z., Su, J., Yang, J., Yang, X., & Wu, Y.-L. L. C. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.961

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,256 · see citing works

Epidemiology of PD-L1 and ALK expression and EGFR mutational status in Argentinian patients with lung cancer.

Salanova, R., Pereyra, J. C. C., Leguina, L., Beña, A., Barberis, M., Vargas, R., del Toro, R. J., Kreimberg, K., & Powazniak, Y. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e20565 · Cited by 3 · see citing works